Targeting the Inflammasome to Treat Chronic Inflammatory Skin Diseases: Clinical & Preclinical Advances in Atopic Dermatitis and Alopecia Areata
Time: 1:30 pm
day: Day One PM
Details:
- Presenting Phase 2 clinical trial data demonstrating the efficacy and safety of a novel inflammasome inhibitor targeting GPCR19 in patients with mild-to-moderate atopic dermatitis
- Highlighting preclinical results in canine models using oral formulation showing potent suppression of NLRP3 inflammasome activation, supporting the development of 2nd generation compounds.
- Sharing early-stage data in alopecia areata showing restoration of hair growth through immune modulation, including inflammasome inhibition and upregulation of regulatory T cells by 2nd generation GPCR19 agonist
- Exploring a dual-acting mechanism that combines inhibition of inflammasome assembly and cytokine signalling as a differentiated strategy for long-term control of chronic skin inflammation such as rosacea and acne
